Lajos Gergely, Vanda Repiska, Juraj Hutnik, Natalia Andova, Lubica Milosovicova, Miroslav Korbel, Liam McCullough, Alexandra Kristufkova, Ludovit Danihel, Helena Gbelcova, Petra Priscakova
{"title":"Genotyping of suspected partial hydatidiform moles - our experiences and future directions.","authors":"Lajos Gergely, Vanda Repiska, Juraj Hutnik, Natalia Andova, Lubica Milosovicova, Miroslav Korbel, Liam McCullough, Alexandra Kristufkova, Ludovit Danihel, Helena Gbelcova, Petra Priscakova","doi":"10.3389/pore.2026.1612410","DOIUrl":null,"url":null,"abstract":"<p><p>This brief research report summarizes our experience with the molecular differential diagnosis of clinically or pathologically suspected partial hydatidiform moles and discusses practical diagnostic options when economic resources or laboratory infrastructure are limited. We analyzed the genome composition of 68 suspected cases using short tandem repeat genotyping based on quantitative fluorescent PCR and fragmentation analysis. Genetic testing excluded a partial mole in 35 cases (51%) by demonstrating a diploid or monogynic monoandric diploid genome, while in 33 cases (49%) a partial mole was confirmed through identification of diandric triploidy (31 cases) or triandric tetraploidy (2 cases). No instances of digynic triploidy were detected in this cohort. Our findings indicate that, in the absence of access to a DNA laboratory, most suspected partial moles can still be accurately evaluated using ploidy assessment by more widely available methods, such as fluorescent <i>in situ</i> hybridization, DNA flow cytometry, or conventional karyotyping, given the apparent rarity of digynic triploidy among these cases.</p>","PeriodicalId":19981,"journal":{"name":"Pathology & Oncology Research","volume":"32 ","pages":"1612410"},"PeriodicalIF":2.7000,"publicationDate":"2026-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13243142/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pathology & Oncology Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/pore.2026.1612410","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
This brief research report summarizes our experience with the molecular differential diagnosis of clinically or pathologically suspected partial hydatidiform moles and discusses practical diagnostic options when economic resources or laboratory infrastructure are limited. We analyzed the genome composition of 68 suspected cases using short tandem repeat genotyping based on quantitative fluorescent PCR and fragmentation analysis. Genetic testing excluded a partial mole in 35 cases (51%) by demonstrating a diploid or monogynic monoandric diploid genome, while in 33 cases (49%) a partial mole was confirmed through identification of diandric triploidy (31 cases) or triandric tetraploidy (2 cases). No instances of digynic triploidy were detected in this cohort. Our findings indicate that, in the absence of access to a DNA laboratory, most suspected partial moles can still be accurately evaluated using ploidy assessment by more widely available methods, such as fluorescent in situ hybridization, DNA flow cytometry, or conventional karyotyping, given the apparent rarity of digynic triploidy among these cases.
期刊介绍:
Pathology & Oncology Research (POR) is an interdisciplinary Journal at the interface of pathology and oncology including the preclinical and translational research, diagnostics and therapy. Furthermore, POR is an international forum for the rapid communication of reviews, original research, critical and topical reports with excellence and novelty. Published quarterly, POR is dedicated to keeping scientists informed of developments on the selected biomedical fields bridging the gap between basic research and clinical medicine. It is a special aim for POR to promote pathological and oncological publishing activity of colleagues in the Central and East European region. The journal will be of interest to pathologists, and a broad range of experimental and clinical oncologists, and related experts. POR is supported by an acknowledged international advisory board and the Arányi Fundation for modern pathology.